Dupixent® (dupilumab) – New indication and new warnings
October 19, 2018 - Regeneron Pharmaceuticals and Sanofi announced the FDA approval of Dupixent (dupilumab), as an add-on maintenance treatment in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma.
Top